It started like a gold rush.
India's biggest pharma names lined up at the gates.
Semaglutide patent expires March 2026? Game on.
Dr Reddy's. Cipla. Zydus. Sun. Alkem. Glenmark. Natco.
Nearly 50 generic brands racing into a single market.
The pitch was irresistible — India's obesity wave, meet India's generic muscle.
Three months in, the music has stopped.
Companies that had penciled in ₹100–150 crore of first-year GLP-1 revenue are now quietly slashing targets by 25–30%.
More than ₹100 crore of unsold inventory is sitting with stockists and wholesalers.
Awkward.
Prescriptions spiked in month one… and then flatlined.
In a brand-new category, that's not supposed to happen.
New categories are meant to keep climbing for months.
Indian generics planned to undercut the innovator and feast.
Novo Nordisk had other plans.
The Danish giant slashed Wegovy and Ozempic starting-dose prices by up to 48% from April 1 — dropping both to around ₹5,660 a month.
The moat the generics were betting on? Gone overnight.
👉 Generic semaglutide still costs ₹2,000–4,000 a month
👉 Innovator Novo is now within striking distance
👉 Margins for desi players got squeezed before they even warmed up
Here's the part nobody wants to say out loud.
Indians are starting GLP-1s. They're not staying on them.
Why?
💸 ₹2,000–4,000 a month is still a stretch for most households
💉 Injection pens are fiddly, intimidating, device-heavy
🤢 Side effects bite hard in the first weeks
🧠 The weight-loss hype outran the patient-education work
No retention. No refills. No recurring revenue.
The whole GLP-1 business model breaks without continuation.
Companies that were sharpening knives for a second wave of launches?
They've gone into wait-and-watch mode.
New brand rollouts are being pushed to Q3 or Q4 of FY27.
The playbook is being rewritten in real time — cheaper pens, oral formats, patient support programs, EMI-style packs.
India's GLP-1 story was never going to be won on price alone.
It'll be won by whoever cracks adherence — keeping a patient on the drug for month 3, month 6, month 12.
The first wave assumed Indians wanted a miracle shot.
Turns out they wanted a habit they could afford to keep.
And that's a much harder drug to sell.
That's all for now!
